ILLUMINA

With over 9,000 patents, we are proud to be a catalyst for our customers and partners. In 2022, Illumina technology drove over 300,000 studies featured in peer-reviewed scientific publications-and we are just getting started. From pathogen surveillance in Africa, to global population health, and pharmacogenomics, our contributions to science are enabling global innovation for our partners and revolutionizing health... At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking..

Also known as: Illumina Australia and New Zealand, Illumina China, Illumina France, Illumina Germany, Illumina India, Illumina India Biotechnology Private Limited, Illumina Israel, Illumina Japan, Illumina Korea, Illumina Netherlands, Illumina Netherlands B.V., Illumina Singapore, Illumina Trading (Shanghai) Co., Ltd., Illumina United Kingdom, Illumina, Inc.

Primary location: San Diego United States